- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07938515
Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Varying Degrees of Renal Impairment and Normal Renal Function
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Trial Participants With Varying Degrees of Renal Impairment and in Those With Normal Renal Function
This Phase 1 study is designed to evaluate the pharmacokinetics and safety of a single oral dose of DA-302168S in subjects with moderate renal impairment (with the possible inclusion of subjects with mild renal impairment), compared with age-, sex-, and body mass index (BMI)-matched subjects with normal renal function. The results of this study will provide scientific evidence to support appropriate clinical dosing recommendations for DA-302168S in subjects with renal impairment.
연구 개요
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: xiaolong qin
- 전화번호: 18781997925
- 이메일: qinxiaolong.cn@outlook.com
연구 장소
-
-
Jiangsu
-
Suzhou, Jiangsu, 중국, 215000
- 모병
- The Second Affiliated Hospital of Soochow University
-
연락하다:
- xiaolong qin
- 전화번호: 18781997925
- 이메일: qinxiaolong.cn@outlook.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age 18-65 years inclusive at ICF signing, male or female; age matching (±10 years) between normal and renal impairment groups, with sex matching as far as possible (±1 participant per sex).
- Weight and BMI at screening: male ≥50.0 kg, female ≥45.0 kg; BMI 19.0-30.0 kg/m² inclusive; weight matching (±10 kg) between normal and renal impairment groups.
- Fertile female or male participants must agree to use reliable contraception for themselves and their partners during the study and for 90 days after dosing (see Appendix 3), and must not donate sperm or oocytes/eggs for assisted reproduction.
- Able to understand the study procedures and methods, voluntarily sign the ICF, and willing to strictly comply with protocol requirements and complete the related procedures.
Exclusion Criteria:
- History or family history of medullary thyroid carcinoma, thyroid C-cell hyperplasia, or MEN2; or screening serum calcitonin ≥50 ng/L.
- History of chronic pancreatitis, or acute pancreatitis within 3 months before ICF signing.
- History of acute gallbladder disease within 3 months before ICF signing.
- Any malignancy within 5 years before ICF signing (except curatively treated basal cell carcinoma considered cured).
- History of severe cardiovascular, neuropsychiatric, gastrointestinal, respiratory, urinary, endocrine, or other systemic disease within 1 year before ICF signing (e.g., acute myocardial infarction, major depression, gastric ulcer, uremia).
- Investigator-judged dysphagia at screening, or conditions possibly affecting drug absorption, distribution, metabolism, or excretion (e.g., active inflammatory bowel disease, gastrectomy, any intestinal resection).
- Severe hypoglycemia within 3 months before screening.
- Participation in any clinical trial within 3 months before screening (except ICF signing only without drug/device intervention), or last dose of investigational drug <5 half-lives before screening.
- History of allergic diseases (e.g., asthma, urticaria, eczematous dermatitis), or known intolerance/allergy to GLP-1 receptor agonists.
- Major surgery within 1 year before screening [major surgery defined as surgery on intracranial, thoracic, abdominal, pelvic, or limb organs causing major tissue trauma and requiring prolonged recovery (e.g., organ transplantation, cardiac surgery, joint replacement)], or planned surgery during the study.
- Blood donation or massive blood loss (≥400 mL) within 3 months before screening or between screening and first dose, or planned blood donation during the study.
- History of drug abuse within 3 years before screening (e.g., morphine, ketamine, THC acid, methamphetamine, MDMA, cocaine) or positive baseline urine drug test.
- Smoking >5 cigarettes/day or habitual use of nicotine-containing products within 3 months before screening, or inability to abstain during the study.
- History of alcohol abuse within 1 year before screening (male >14 standard units/week, female >7 standard units/week; 1 standard unit = 14 g alcohol, e.g., 360 mL beer, 45 mL 40% spirits, or 150 mL wine), or positive baseline breath/blood alcohol test.
- Special dietary requirements and inability to accept a standardized diet.
- Consumption of grapefruit-rich beverages or foods within 7 days before first dose, or unwillingness to stop during the study.
- Vaccination within 30 days before dosing, or planned vaccination within 30 days after dosing.
- Inability to avoid strenuous exercise or other behaviors possibly affecting PK parameters from 48 h before dosing through the study.
- History of needle/blood phobia, difficult blood collection, or intolerance to venipuncture.
- Pregnant or lactating women.
- Participant is an investigator or other related research staff for this project.
- Any other condition that, in the investigator's opinion, makes the participant unsuitable for the study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Group A
Subjects with moderate renal impairment |
Small molecule GLP-1RA tablet |
|
실험적: Group B
Subjects with moderate renal impairment |
Small molecule GLP-1RA tablet |
|
위약 비교기: Group C
Subjects with normal renal function matched to renal impairment subjects |
Small molecule GLP-1RA tablet |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Peak Plasma Concentration (Cmax) of DA-302168S
기간: Predose up to 72 hours postdose (D1 to D4)
|
Predose up to 72 hours postdose (D1 to D4)
|
|
Area Under the Serum Concentration Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of DA-302168S
기간: Predose up to 72 hours postdose (D1 to D4)
|
Predose up to 72 hours postdose (D1 to D4)
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 2026-CP-DA168-14
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .